Statin therapy in patients with community acquired pneumonia

Research output: Contribution to journalArticlepeer-review

Colleges, School and Institutes

External organisations

  • Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham

Abstract

Community acquired pneumonia (CAP) is the leading cause of death from infection in developed countries. There is evidence of an association between improved survival from infection and statin use. The possible beneficial effects of statins are complicated by the common use of macrolide antibiotics for pneumonia with current guidance suggesting that concurrent macrolide and statin use is contra-indicated. We conducted an observational study of statin use in patients with CAP. Of 2067 with CAP, 30.4% were on statin therapy at admission. Statin users were more likely to survive the admission (p<0.001). In addition, we conducted a survey of doctors and found that knowledge regarding concurrent macrolide and statin use was lacking. These data suggest a potential role of statins in the management of CAP. Further research using high dose statins is required to assess their safe use in subjects with mild to moderate infections.

Details

Original languageEnglish
Pages (from-to)403-407
JournalClinical Medicine
Volume17
Issue number5
Publication statusPublished - 1 Oct 2017

Keywords

  • immunomodulatory drugs , macrolide antibiotic , pneumonia , sepsis , statin